杜平杰;李杨;

• 1:川北医学院附属医院放射科

摘要(Abstract)：

肝细胞癌是病死率高的恶性肿瘤之一。医学影像成像在肝癌的筛查和诊断中具有重要的临床意义。磁共振分子成像是一种具有广阔应用前景的重要诊断工具。本文介绍了分子成像的基本定义,并讨论了肝细胞癌磁共振成像的相关靶点。

关键词(KeyWords)： 肝癌;分子成像;磁共振成像;成像靶点

Abstract:

Keywords:

基金项目(Foundation): 四川省教育厅重点项目（17ZA0186）;; 南充市市校合作科研专项基金项目（NSMC20170431）;; 川北医学院博士科研启动基金项目（CBY15-QD11）

作者(Author): 杜平杰;李杨;

Email:

DOI:

参考文献(References)：

• 1 Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
• 2 陈万青,崔富强,樊春笋,等.中国肝癌一级预防专家共识(2018)[J].临床肝胆病杂志, 2018, 34(10):2090-2097.
• 3 Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14(CONCORD-3):analysis of individual records for 37 513 025 patients diagnosed with one of 18cancers from 322 population-based registries in 71 countries[J].Lancet, 2018, 391(10125):1023-1075.
• 4 Kierans AS, Kang SK, Rosenkrantz AB. The diagnostic performance of dynamic contrast-enhanced MR imaging for detection of small hepatocellular carcinoma measuring up to 2 cm:A Meta-Analysis[J].Radiology, 2016, 278(1):82-94.
• 5 Anderson CJ, Lewis JS. Current status and future challenges for molecular imaging[J]. Philos Trans A Math Phys Eng Sci, 2017, 375(2107):20170023.
• 6 James ML, Gambhir SS. A molecular imaging primer:modalities,imaging agents, and applications[J]. Physiol Rev, 2012, 92(2):897-965.
• 7 Liang G, Nguyen PK. Molecular probes for cardiovascular imaging[J].J Nucl Cardiol, 2016, 23(4):783-789.
• 8 Son J, Hwang SH, Park S, et al. Imaging features of hepatocellular carcinoma:quantitative and qualitative comparison between MRIEnhanced with Gd-EOB-DTPA and Gd-DTPA[J]. Invest Radiol,2019, 54(8):494-499.
• 9 Guggenheim EJ, Rappoport JZ, Lynch I. Mechanisms for cellular uptake of nanosized clinical MRI contrast agents[J]. Nanotoxicology,2020, 14(4):504-532.
• 10 Vallabani N, Singh S. Recent advances and future prospects of iron oxide nanoparticles in biomedicine and diagnostics[J]. 3 Biotech,2018, 8(6):279.
• 11 Najafabadi RE, Kazemipour N, Esmaeili A, et al. Quercetin prevents body weight loss due to the using of superparamagnetic iron oxide nanoparticles in rat[J]. Adv Biomed Res, 2018, 7:8.
• 12 Ma X, Wang S, Hu L, et al. Imaging characteristics of USPIO nanoparticles(<5 nm)as MR contrast agent in vitro and in the liver of rats[J]. Contrast Media Mol Imaging, 2019, 2019:3687537.
• 13 Chen W, Shen B, Sun X. Analysis of progress and challenges of EGFR-targeted molecular imaging in cancer with a focus on affibody molecules[J]. Mol Imaging, 2019, 18:1330212303.
• 14 Bellissimo F, Pinzone MR, Cacopardo B, et al. Diagnostic and therapeutic management of hepatocellular carcinoma[J]. World J Gastroenterol, 2015, 21(42):12003-12021.
• 15 宋吉慧. AFP靶向USPIO分子探针在肝癌特异性MR成像中的价值[D].济南:山东大学, 2012.
• 16 Li YW, Chen ZG, Zhao ZS, et al. Preparation of magnetic resonance probes using one-pot method for detection of hepatocellular carcinoma[J]. World J Gastroenterol, 2015, 21(14):4275-4283.
• 17 Zhou F, Shang W, Yu X, et al. Glypican-3:A promising biomarker for hepatocellular carcinoma diagnosis and treatment[J]. Med Res Rev,2018, 38(2):741-767.
• 18 El-Saadany S, El-Demerdash T, Helmy A, et al. Diagnostic value of glypican-3 for hepatocellular carcinomas[J]. Asian Pac J Cancer Prev,2018, 19(3):811-817.
• 19 Zhao M, Liu Z, Dong L, et al. A GPC3-specific aptamer-mediated magnetic resonance probe for hepatocellular carcinoma[J]. Int J Nanomedicine, 2018, 13:4433-4443.
• 20 Ma XH, Wang S, Liu SY, et al. Development and in vitro study of a bispecific magnetic resonance imaging molecular probe for hepatocellular carcinoma[J]. World J Gastroenterol, 2019, 25(24):3030-3043.
• 21 Atta MM, Atta HM, Gad MA, et al. Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients[J]. J Hepatocell Carcinoma, 2016, 3:19-24.
• 22 潘奇,罗春海,马婉玲,等.血管内皮生长因子C靶向分子探针在肝细胞癌大鼠模型中的特异性磁共振成像及临床意义[J].临床肝胆病杂志, 2018, 34(7):1492-1496.
• 23 潘奇,罗春海,马婉玲,等. VEGF-C靶向USPIO分子探针的构建及其对肝癌细胞HepG2分子成像的初步研究[J].医学影像学杂志,2018, 28(9):1557-1560.
• 24 Hu Q, Wang XY, Kang LK, et al. RGD-targeted ultrasound contrast agent for longitudinal assessment of Hep-2 tumor angiogenesis in vivo[J]. PLoS One, 2016, 11(2):e149075.
• 25 赵荣荣,韩明,程鑫,等. MR分子探针RGD-USPIO评价核苷组合对人肝癌细胞Bel-7402的作用[J].中国医学影像技术, 2017, 33(8):1163-1166.
• 26 Jia Z, Song L, Zang F, et al. Active-target T1-weighted MR imaging of tiny hepatic tumor via RGD modified ultra-small Fe3O4nanoprobes[J].Theranostics, 2016, 6(11):1780-1791.
• 27 Sid V, Siow YL, Karmin O. Role of folate in nonalcoholic fatty liver disease[J]. Can J Physiol Pharmacol, 2017, 95(10):1141-1148.
• 28 唐纳,赵光明,李征宇,等. NP-DA-Dextra-FA靶向纳米分子探针对人肝癌细胞的体外磁共振成像研究[J].磁共振成像, 2017, 8(8):604-608.
• 29 Li L, Gao F, Jiang W, et al. Folic acid-conjugated superparamagnetic iron oxide nanoparticles for tumor-targeting MR imaging[J]. Drug Deliv, 2016, 23(5):1726-1733.
• 30 Sanjai C, Kothan S, Gonil P, et al. Super-paramagnetic loaded nanoparticles based on biological macromolecules for in vivo targeted MR imaging[J]. Int J Biol Macromol, 2016, 86:233-241.